ClinicalTrials.gg
CompletedNCT06881264Updated Jan 27, 2026

A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

A Phase 3 interventional study of HR17031 injection and insulin glargine in Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Apr 2024, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
56th of 175
401 · median 253
Started
2024
with 3 others
Phase 3
60 of 176
1 open now
Registered
174th of 176
by date

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 56th largest by enrollment of the 175 interventional ones that give a count, is one of 4 that started in 2024, is one of 60 in phase 3, and was the 174th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

03

Conditions studied

  • Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18-75 years at the time of signing the (both ends included);
  2. (BMI) of 20.0-40.0 kg/m2 (both ends included);
  3. Diagnosed with type 2 diabetes for at least 90 days prior to screening;
  4. Tested by local laboratory, is 7.5%-11% (including both ends);
  5. Before screening, the daily basal insulin dose had been stabilized at 20-40 U/day (including both ends) for at least 60 days;
  6. When screening: ① metformin monotherapy stable treatment ≥ 3 months; or ② metformin combined with another OAD for stable treatment for ≥ 3 months; Metformin dose ≥ 1500 mg/day or maximum tolerated dose.
  7. Ability and willingness to comply with protocol requirements, including self-monitoring of blood glucose, recording subject diary, and using pre-filled injection pen.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to the drug product or its components or ;
  2. Systemic use within 3 months prior to screening;
  3. Use of weight loss drugs within 3 months prior to screening;
  4. Received insulin therapy within 1 year prior to screening (excluding short-term therapy [continuous treatment ≤14 days] or insulin therapy for gestational diabetes);
  5. Cardiovascular disease, defined as congestive heart failure ( III-IV), unstable angina pectoris, stroke (except lacunar infarction without symptoms), myocardial infarction, coronary revascularization within 6 months prior to screening; And/or coronary, carotid, or peripheral arterial revascularization is planned at screening;
  6. (with or without treatment) uncontrolled severe hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
  7. Proliferative retinopathy or macular degeneration requiring acute treatment, painful diabetic neuropathy, diabetic foot ulcers, intermittent claudication at screening;
  8. Patients diagnosed with mental disorders; Mentally incapacitated or speech impediment, unable to fully understand the trial protocol or unwilling to collaborate;
  9. Known or suspected abuse of alcohol or narcotics;
  10. Previous history of pancreatitis (acute or chronic);
  11. During pregnancy or lactation;fertile women () or men who have fertility plan or unwilling to use appropriate methods from the signing of the to 3 months after last use of the investigational drug product;
  12. Any condition, determined by the investigator, interfere with the efficacy or safety results of the trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Treatment group A: HR17031 injection

    Drug: HR17031 injection

  • Experimental
    Treatment group B: insulin glargine

    Drug: insulin glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c: Changes in HbA1c from baseline to week 26

    Time frame: week 26

Secondary outcomes

  1. Proportion of subjects achieved HbA1c<7.0% at week 26

    Time frame: at week 26

  2. Change in body weight from baseline after 26 weeks of treatment

    Time frame: 26 weeks

  3. Proportion of subjects achieved HbA1c<7.0% without body weight gain at week 26

    Time frame: week 26

  4. Actual Daily Insulin dose at week 26

    Time frame: week 26

  5. Proportion of subjects achieved HbA1c≤6.5% at week 26

    Time frame: week 26

  6. Changes in Fasting Plasma Glucose (FPG) after 26 weeks of treatment

    Time frame: 26 weeks

  7. Proportion of subjects achieved HbA1c≤6.5%without body weight gain at week 26

    Time frame: week 26

  8. Proportion of subjects achieved HbA1c<7.0% without Level 2 and Level 3 hypoglycemic event after 12weeks treatment

    Time frame: 12weeks

  9. Proportion of subjects achieved HbA1c≤6.5% without Level 2 and Level 3 hypoglycemic event after 12weeks treatment

    Time frame: 12weeks

  10. Proportion of subjects achieved HbA1c<7.0% without body weight gain and without Level 2 and Level 3 hypoglycemic event after 12weeks treatment at week 26

    Time frame: at week 26

  11. Proportion of subjects achieved HbA1c≤6.5% without body weight gain and without Level 2 and Level 3 hypoglycemic event after 12weeks treatment at week 26

    Time frame: at week 26

  12. Proportion of subjects achieved HbA1c<5.7% at week 26

    Time frame: at week 26

  13. Change in mean of the 7-point SMPG profile from baseline (week 0) to week 26;

    Time frame: week 26;

  14. Change from baseline (week 0) in post-prandial SMPG increments for all meals after 26 weeks of treatment

    Time frame: 26 weeks

  15. Changes in HbA1c from baseline after 52 weeks of treatment

    Time frame: 52 weeks

  16. Changes in FBG from baseline after 52 weeks of treatment

    Time frame: 52 weeks

  17. Changes in body weight from baseline after 52 weeks of treatment

    Time frame: 52 weeks

  18. Proportion of subjects achieved HbA1c<7% at week 52

    Time frame: at week 52

  19. Proportion of subjects achieved HbA1c≤6.5% at week 52

    Time frame: at week 52

  20. Proportion of subjects achieved HbA1c<7% without body weight gain at week 52

    Time frame: at week 52

  21. Proportion of subjects achieved HbA1c≤6.5% without body weight gain at week 52

    Time frame: at week 52

  22. Proportion of subjects achieved HbA1c<7.0% without Level 2 and Level 3 hypoglycemic event after 12weeks treatment at week 52

    Time frame: at week 52

  23. Proportion of subjects achieved HbA1c<7.0% without body weight gain and without Level 2 and Level 3 hypoglycemic event after 12weeks treatment at week 52

    Time frame: at week 52

  24. Proportion of subjects achieved HbA1c≤6.5% without body weight gain and without Level 2 and Level 3 hypoglycemic event after 12weeks treatment at week 52

    Time frame: at week 52

  25. Proportion of subjects achieved HbA1c<5.7% at week 52

    Time frame: at week 52

  26. Change in mean of the 7-point SMPG profile from baseline (week 0) to week 52

    Time frame: week 52

  27. Change from baseline (week 0) in post-prandial SMPG increments for all meals after 52 weeks of treatment

    Time frame: 52 weeks

  28. Actual Daily Insulin dose at week 52

    Time frame: at week 52

  29. Number of Treatment-emergent Hypoglycemic event from screening to week 53

    Time frame: from screening to week 53

  30. Number of Treatment-emergent Adverse Events from screening to week 53

    Time frame: from screening to week 53

  31. Number of participants who were assessed for anti-insulin glargine antibodies, anti-INS068 antibodies and anti-HR20004 antibodies at week 27

    Time frame: at week 27

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Sep 2025, 16 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 18, 2025
StartActual
Apr 30, 2024
Primary completionActual
Sep 19, 2025
CompletionActual
Sep 19, 2025
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06881264
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Apr 30, 2024
Primary completion
Sep 19, 2025
Completion
Sep 19, 2025
Last update
Jan 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HR17031 · Insulin Glargine

Start the discussion